{
 "ticker": "PBPH",
 "name": "Portfolio Building Block World Pharma and Biotech Index ETF",
 "issuer": "not established",
 "desk": "themes",
 "url": "https://etfiq.com/funds/PBPH",
 "html": "https://etfiq.com/funds/PBPH",
 "markdown": "https://etfiq.com/funds/PBPH.md",
 "as_of": "2026-09-11",
 "verdict": "PBPH holds 51 stocks, and 43% of its weight is outside the S&P 500.",
 "key_facts": [
  {
   "key": "already_in_the_s_p_500",
   "label": "Already in the S&P 500",
   "value": "56.8%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "PBPH, already in the S&P 500: 56.8%, as of Sep 11, 2026."
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "95.0%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "PBPH, active share vs the S&P 500: 95.0%, as of Sep 11, 2026."
  },
  {
   "key": "top_ten_holdings",
   "label": "Top ten holdings",
   "value": "62.7%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "PBPH, top ten holdings: 62.7%, as of Sep 11, 2026."
  },
  {
   "key": "total_return_since_launch",
   "label": "Total return, since launch",
   "value": "+11.0%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "PBPH, total return, since launch: +11.0%, as of Sep 11, 2026."
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$36m",
   "source": "SEC filing, whole fund, as filed for Jan 31, 2026",
   "as_of": "2026-09-11",
   "sentence": "PBPH, net assets: $36m (SEC filing, whole fund, as filed for Jan 31, 2026)."
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.13%",
   "source": "485BPOS XBRL, Oct 27, 2025",
   "as_of": "2026-09-11",
   "sentence": "PBPH, expense ratio: 0.13% (485BPOS XBRL, Oct 27, 2025)."
  }
 ],
 "fields": [
  {
   "key": "theme",
   "label": "Theme",
   "value": "Biotech and genomics",
   "source": "ETFIQ, editorial"
  },
  {
   "key": "launched",
   "label": "Launched",
   "value": "Nov 25, 2025",
   "source": null
  },
  {
   "key": "already_in_the_s_p_500_by_weight",
   "label": "Already in the S&P 500, by weight",
   "value": "56.8%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "95.0%",
   "source": "ETFIQ"
  },
  {
   "key": "already_in_the_nasdaq_100_by_weight",
   "label": "Already in the Nasdaq-100, by weight",
   "value": "14.7%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_nasdaq_100",
   "label": "Active share vs the Nasdaq-100",
   "value": "97.4%",
   "source": "ETFIQ"
  },
  {
   "key": "top_ten_holdings_weight",
   "label": "Top ten holdings weight",
   "value": "62.7%",
   "source": null
  },
  {
   "key": "holdings",
   "label": "Holdings",
   "value": "51",
   "source": null
  },
  {
   "key": "holdings_as_of",
   "label": "Holdings as of",
   "value": "Jan 31, 2026",
   "source": "SEC N-PORT"
  },
  {
   "key": "top_holdings",
   "label": "Top holdings",
   "value": "ELI LILLY & CO 14.7%, JOHNSON & JOHNSON 9.1%, ABBVIE INC 6.5%, ROCHE HOLDING AG-GENUSSCHEIN 5.3%, NOVARTIS AG-REG 5.0%, MERCK & CO. INC. 4.7%, ASTRAZENECA PLC 4.6%, NOVO NORDISK A/S-B 4.4%, AMGEN INC 4.3%, GILEAD SCIENCES INC 4.1%",
   "source": null
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$36m",
   "source": "SEC filing, whole fund, as filed for Jan 31, 2026"
  },
  {
   "key": "below_its_all_time_high",
   "label": "Below its all-time high",
   "value": "\u22126.7%",
   "source": "ETFIQ"
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.13%",
   "source": "485BPOS XBRL, Oct 27, 2025"
  },
  {
   "key": "fee_for_the_part_that_differs_from_the_s_p_500_active_expense_ratio",
   "label": "Fee for the part that differs from the S&P 500, active expense ratio",
   "value": "0.14%",
   "source": "ETFIQ"
  },
  {
   "key": "closest_funds_by_holdings_overlap",
   "label": "Closest funds by holdings overlap",
   "value": "GDOC 37%, THNR 34%, BMED 32%, AGNG 32%, CANC 31%",
   "source": null
  }
 ],
 "periods": [
  {
   "window": "3 months",
   "Total return": "+7.1%",
   "S&P 500": "+3.3%",
   "Gap to S&P 500": "+3.8 pts",
   "Gap to Nasdaq-100": "+7.9 pts"
  },
  {
   "window": "6 months",
   "Total return": "+9.2%",
   "S&P 500": "+16.0%",
   "Gap to S&P 500": "\u22126.9 pts",
   "Gap to Nasdaq-100": "\u221211.5 pts"
  },
  {
   "window": "Since launch",
   "Total return": "+11.0%",
   "S&P 500": "+14.2%",
   "Gap to S&P 500": "\u22123.2 pts",
   "Gap to Nasdaq-100": "\u22126.8 pts"
  }
 ],
 "questions": [
  {
   "q": "How much of PBPH is in S&P 500 companies?",
   "a": "By its holdings filed for Jan 31, 2026, 57% of PBPH by weight is stocks the S&P 500 already holds. Its active share against the index is 95%, so that share is the part doing something different."
  },
  {
   "q": "What does PBPH hold?",
   "a": "51 positions as filed for Jan 31, 2026, with the top ten at 63% of the fund. The largest are ELI LILLY & CO at 14.7%, JOHNSON & JOHNSON at 9.1%, ABBVIE INC at 6.5%."
  },
  {
   "q": "Has PBPH beaten the S&P 500?",
   "a": "Over the year to Sep 11, 2026 PBPH returned +11.0% with distributions reinvested, against +14.2% for the S&P 500, so it finished behind the index by 3.2 points."
  },
  {
   "q": "What does PBPH cost?",
   "a": "The prospectus expense ratio is 0.13% a year. Because 95% of the fund differs from the S&P 500, the fee on that differing part works out at 0.14%."
  }
 ],
 "generated": "2026-09-13",
 "license": "Free to use with attribution. ETFIQ (etfiq.com)."
}